Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 2/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | CA9 | Q16790 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 4/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | KDM5A | P29375 | 3/20 | 0.38 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | MMP1 | P03956 | 1/20 | 0.38 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | MMP3 | P08254 | 1/20 | 0.38 |
| ▸ | MMP8 | P22894 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16526222 | 0.93 | KDM5A (0.44) | LMNAACHEEPHX2KDM5AKDM4C | |
| SCHEMBL305640 | 0.91 | KDM5A (0.45) | LMNAACHEEPHX2KDM5AKDM4C | |
| SCHEMBL28688844 | 0.91 | KDM5A (0.45) | LMNAACHEEPHX2KDM5AKDM4C | |
| SCHEMBL29197968 | 0.90 | KDM5A (0.44) | LMNAACHEEPHX2KDM5AEPHX1 | |
| SCHEMBL3478490 | 0.86 | — | — | |
| SCHEMBL14707175 | 0.83 | MEN1 (0.42) | ALDH1A1LMNAACHE | |
| SCHEMBL22203118 | 0.82 | LMNA (0.44) | ALDH1A1LMNAKDM5AKDM4C | |
| SCHEMBL22282294 | 0.82 | LMNA (0.40) | ALDH1A1MAPTLMNA | |
| SCHEMBL11850308 | 0.81 | TDP1 (0.36) | ALDH1A1MAPTTDP1CA12CA1 | |
| SCHEMBL18723043 | 0.80 | CA2 (0.45) | ALDH1A1TDP1CA1LMNAMMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023109878-A1 | TRIAZASPIRO LPAR1 ANTAGONIST AND USE THEREOF | 武汉人福创新药物研发中心有限公司 | 2023-06-22 | — | — | WO | disclosed |
| WO-2022221704-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING CANCER | HOTSPOT THERAPEUTICS, INC. (US) | 2022-10-20 | — | — | WO | disclosed |
| CN-110546135-B | Method for producing isocyanate | 旭化成株式会社 | 2021-12-14 | — | — | CN | disclosed |
| CN-112020493-A | Method for producing carbamate and method for producing isocyanate | 旭化成株式会社 | 2020-12-01 | — | — | CN | disclosed |
| CN-110546135-A | Method for producing isocyanate | ASAHI CHEMICAL IND | 2019-12-06 | — | — | CN | disclosed |
| US-9849107-B2 | Compositions and methods for inhibiting cytochrome P450 | SEQUOIA PHARMACEUTICALS, INC. (US) | 2017-12-26 | — | — | US | disclosed |
| US-20170354636-A1 | METHODS FOR INHIBITING TUMORS AND DRUG RESISTANCE | SEQUOIA PHARMACEUTICALS INC (US) | 2017-12-14 | — | — | US | disclosed |
| US-20160361287-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CYTOCHROME P450 | SEQUOIA PHARMACEUTICALS, INC. | 2016-12-15 | — | — | US | disclosed |
| US-9233952-B2 | Compositions and methods for inhibiting cytochrome P450 | SEQUOIA PHARMACEUTICALS, INC. (US) | 2016-01-12 | — | — | US | disclosed |
| US-20150284352-A1 | METHODS FOR INHIBITING DRUG DEGRADATION | SEQUOIA PHARMACEUTICALS INC (US) | 2015-10-08 | — | — | US | disclosed |
| WO-2014144169-A1 | CARM1 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2014-09-18 | — | — | WO | disclosed |
| US-8673970-B2 | HIV protease inhibitor and cytochrome p450 inhibitor combinations | SEQUOIA PHARMACEUTICALS, INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-20140024671-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CYTOCHROME P450 | SEQUOIA PHARMACEUTICALS INC (US) | 2014-01-23 | — | — | US | disclosed |
| US-8481520-B2 | Compositions and methods for inhibiting cytochrome P450 | SEQUOIA PHARMACEUTICALS, INC. (US) | 2013-07-09 | — | — | US | disclosed |
| EP-0678504-B1 | A process for producing substituted amines and a method for purifying synthetic intermediates therefor | MITSUI CHEMICALS INC (JP) | 2000-06-21 | — | — | EP | disclosed |
| US-5932759-A | HYDROLYSIS OF A HYDROXAMIC ACID IN PRESENCE OF A BASE | MITSUI CHEMICALS, INC. (JP) | 1999-08-03 | — | — | US | disclosed |
| US-5510511-A | REACTING HYDROXYLAMINE AND DIHYDROCARBYL CARBONATE WITH COOLING IN PRESENCE OF BASIC COMPOUND, ALKYLATING TO FORM N,O-DIALKYLHYDROXYCARBAMIC ACID ESTER | MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) | 1996-04-23 | — | — | US | disclosed |
| EP-0692469-A1 | Process for recovering N,O-dialkylhydroxycarbamic acid ester | MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) | 1996-01-17 | — | — | EP | disclosed |
| EP-0678504-A2 | A process for producing substituted amines and a method for purifying synthetic intermediates therefor | MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) | 1995-10-25 | — | — | EP | disclosed |
| EP-0581613-A1 | Process for preparing N,O-dialkylhydroxycarbamic acid esters | MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) | 1994-02-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160361287-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CYTOCHROME P450 | CYP3A43, CYP2E1, CYP7A1 | ALDH1A1 363/4885MAPT 3809/4885TDP1 1375/4885 |
| US-20170354636-A1 | METHODS FOR INHIBITING TUMORS AND DRUG RESISTANCE | HCCS, CYP2E1, CYP7A1 | ALDH1A1 308/4885MAPT 4370/4885TDP1 3756/4885 |
| US-20140024671-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CYTOCHROME P450 | CYP3A43, CYP2E1, CYP7A1 | ALDH1A1 363/4885MAPT 3809/4885TDP1 1375/4885 |
| US-20150284352-A1 | METHODS FOR INHIBITING DRUG DEGRADATION | CYP2E1, CYP3A43, CYP3A5 | ALDH1A1 262/4885MAPT 3314/4885TDP1 1383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.